Sanofi Reports Strong Q4 with Net Income Growth and EPS Rise

Sanofi reports a robust fourth quarter, with net income soaring to €880M. Revealing strong earnings per share, the company sees positive sales trends and forecasts continued growth.

Date: 30-01-2025

AI Rating: 6

Net Income and Earnings Per Share (EPS)
Sanofi has shown a significant improvement in net income, reporting €880 million from continuing operations in the fourth quarter, a stark contrast to last year's loss of €119 million. The basic earnings per share from continuing operations was €0.69, recovering from a loss of €0.09, indicating a positive turnaround.

Business Earnings and Revenue Growth
Despite the positive turnaround, the business net income decreased to €1.64 billion from €1.93 billion, marking a decline. Business earnings per share also fell by 14.9%, to €1.31. However, the company's net sales increased by 9.1% to reach €10.56 billion, showcasing notable revenue growth.

Forecast for 2024 and Beyond
Looking ahead to fiscal 2024, Sanofi expects business earnings per share of €7.12, which reflects a slight decrease of 1.8%, but an increase of 4.1% when adjusted for currency effects. The net sales forecast of €41.08 billion represents a growth of 8.6% or 11.3% at constant exchange rates, maintaining a positive trajectory in sales growth.

CEO's Outlook
Paul Hudson, the CEO, expressed confidence in achieving continued sales growth and a strong rebound in earnings as they enter 2025. The expected mid-to-high single-digit percentage growth in sales at CER and low double-digit percentage growth in business EPS before share buyback indicates overall optimism for Sanofi's future.

Stocks: SNY